GA
BLPH

Geneva Advisors’s Bellerophon Therapeutics, Inc. BLPH Stock Holding History

Geneva Advisors’s Portfolio BLPH Stock Details BLPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		$17K Hold
833
– – ﹤0.01% 722
2017
Q1 		$19K Hold
833
– – ﹤0.01% 749
2016
Q4 		$7K Hold
833
– – ﹤0.01% 754
2016
Q3 		$18K Hold
833
– – ﹤0.01% 730
2016
Q2 		$22K Hold
833
– – ﹤0.01% 687
2016
Q1 		$31K Buy
+833
New +$30.9K ﹤0.01% 678

Other funds holding BLPH

NMVA
New Mountain Vantage Advisers New York $4.33B AUM 35.3% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
SIM
Spark Investment Management New York $41.6M AUM 80.97% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Geneva Advisors's BLPH Position: Q2 2017 in Review

Geneva Advisors held its Bellerophon Therapeutics, Inc. (BLPH) position steady in Q2 2017 at 833 shares worth $17K. The position accounts for ﹤0.01% of the portfolio, ranked #722.

Geneva Advisors first reported a position in BLPH in Q1 2016 and has held it in 6 quarters since. The position peaked at $31K in Q1 2016. 20 funds tracked by Wall St. Rank hold BLPH as of Q2 2017.

  • Geneva Advisors held 833 shares of Bellerophon Therapeutics, Inc. worth $17K as of Q2 2017.
  • Geneva Advisors left its Bellerophon Therapeutics, Inc. share count unchanged in Q2 2017.
  • Bellerophon Therapeutics, Inc. made up ﹤0.01% of Geneva Advisors's portfolio in Q2 2017, its #722 holding.
  • Geneva Advisors first reported a position in Bellerophon Therapeutics, Inc. in Q1 2016 and has held it in 6 quarters since.
  • Geneva Advisors's Bellerophon Therapeutics, Inc. position peaked at $31K in Q1 2016.
  • 20 funds tracked by Wall St. Rank held Bellerophon Therapeutics, Inc. as of Q2 2017.

Based on Geneva Advisors's 13F filing for Q2 2017, filed 7 Aug 2017.